Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
42
ANIP Quote, Financials, Valuation and Earnings
Last price:
$82.67
Seasonality move
:
6.29%
Day range:
$81.59 - $83.47
52-week range:
$52.50 - $99.50
Dividend yield:
0%
P/E ratio:
50.70x
P/S ratio:
2.02x
P/B ratio:
3.67x
Volume:
390.9K
Avg. volume:
459.4K
1-year change:
45.52%
Market cap:
$1.9B
Revenue:
$614.4M
EPS (TTM):
$1.63
Analysts' Opinion
-
Consensus RatingANI Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $109.88, ANI Pharmaceuticals, Inc. has an estimated upside of 32.91% from its current price of $82.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $90.00 representing -8.87% downside risk from its current price of $82.74.
Fair Value
-
According to the consensus of 5 analysts, ANI Pharmaceuticals, Inc. has 32.91% upside to fair value with a price target of $109.88 per share.
ANIP vs. S&P 500
-
Over the past 5 trading days, ANI Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ANI Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ANI Pharmaceuticals, Inc. has grown year-over-year revenues for 16 quarters straight. In the most recent quarter ANI Pharmaceuticals, Inc. reported revenues of $227.8M.
Earnings Growth
-
ANI Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter ANI Pharmaceuticals, Inc. reported earnings per share of $1.13.
Enterprise value:
2.2B
EV / Invested capital:
1.95x
Price / LTM sales:
2.02x
EV / EBIT:
41.49x
EV / Revenue:
2.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
16.29x
Price / Operating cash flow:
12.29x
Enterprise value / EBITDA:
15.30x
Gross Profit (TTM):
$414.2M
Return On Assets:
2.7%
Net Income Margin (TTM):
4.32%
Return On Equity:
8.22%
Return On Invested Capital:
3.31%
Operating Margin:
10.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $449.4M | $555.5M | $826.9M | $148.3M | $227.8M | |
| Gross Profit | $225.9M | $271.8M | $414.2M | $69.5M | $111.8M | |
| Operating Income | $45.8M | $9.6M | $53.4M | -$19.7M | $22.8M | |
| EBITDA | $105.8M | $69.9M | $144.8M | -$3.9M | $45.5M | |
| Diluted EPS | $0.60 | -$0.54 | $1.63 | -$1.27 | $1.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $191.1M | $309.2M | $497M | $521.1M | $698.2M | |
| Total Assets | $470.5M | $739.1M | $889.9M | $1.3B | $1.4B | |
| Current Liabilities | $84.9M | $81.6M | $134.4M | $189.9M | $270.6M | |
| Total Liabilities | $279.1M | $402.4M | $460.1M | $881.4M | $902.3M | |
| Total Equity | $191.4M | $336.7M | $429.9M | $405.9M | $505.8M | |
| Total Debt | $202.2M | $288.2M | $310.7M | $650.2M | $631.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $69.8M | $92.9M | $170.7M | $12.5M | $44.1M | |
| Cash From Investing | -$16.9M | -$398.8M | -$43.6M | -$398.5M | -$6.2M | |
| Cash From Financing | $78.8M | $257.9M | -$10.2M | $291M | $6.3M | |
| Free Cash Flow | $52.9M | $73.6M | $136M | $7M | $37.9M | |
ANIP
Sector
Market Cap
$1.9B
$28.4M
Price % of 52-Week High
83.09%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-3.29%
-1.32%
1-Year Price Total Return
45.37%
-22.19%
Beta (5-Year)
0.484
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$83.18
200-day SMA
Buy
Level
$75.30
Bollinger Bands (100)
Sell
Level
76.21 - 96.69
Chaikin Money Flow
Sell
Level
-527.4K
20-day SMA
Sell
Level
$84.05
Relative Strength Index (RSI14)
Sell
Level
40.81
ADX Line
Sell
Level
37.19
Williams %R
Neutral
Level
-52.7273
50-day SMA
Sell
Level
$88.91
MACD (12, 26)
Sell
Level
-2.00
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
11.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4825)
Sell
CA Score
(Annual)
Level (-0.7764)
Buy
Beneish M-Score
(Annual)
Level (-2.3958)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.2319)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Stock Forecast FAQ
In the current month, ANIP has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ANIP average analyst price target in the past 3 months is $109.88.
-
Where Will ANI Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ANI Pharmaceuticals, Inc. share price will rise to $109.88 per share over the next 12 months.
-
What Do Analysts Say About ANI Pharmaceuticals, Inc.?
Analysts are divided on their view about ANI Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ANI Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $90.00.
-
What Is ANI Pharmaceuticals, Inc.'s Price Target?
The price target for ANI Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $109.88 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ANIP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ANI Pharmaceuticals, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ANIP?
You can purchase shares of ANI Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ANI Pharmaceuticals, Inc. shares.
-
What Is The ANI Pharmaceuticals, Inc. Share Price Today?
ANI Pharmaceuticals, Inc. was last trading at $82.67 per share. This represents the most recent stock quote for ANI Pharmaceuticals, Inc.. Yesterday, ANI Pharmaceuticals, Inc. closed at $82.74 per share.
-
How To Buy ANI Pharmaceuticals, Inc. Stock Online?
In order to purchase ANI Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ANIP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ANIP
Sector
P/E ratio
50.70x
23.66x
PEG ratio
--
-0.01x
P/B ratio
3.67x
1.84x
Price / LTM sales
2.02x
1.60x
Growth Metrics
ANIP
Sector
Revenue growth
53.58%
4.85%
Earnings growth
189.47%
11.15%
Revenue (5-year growth)
24.36%
6.45%
Earnings forecast
$1.77
-$0.20
Profitability
ANIP
Sector
Profitability FY 2024
$296.4M
$3.6M
Return on invested capital
3.31%
-30.98%
Return on assets
2.7%
-27.62%
Return on equity
8.22%
-36.69%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Feb
27
Estimated Next Earnings Date
Feb
6
Balance Sheet
ANIP
Sector
Total cash
$271.5M
$27.2M
Short term investments
$6.3M
$25.7M
Total assets
$1.3B
$79.9M
Long term debt
$631.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
